N-Triphenylmethyl-propionamid | 20808-84-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 三苯基化合物
• 英文名称: N-Triphenylmethyl-propionamid
• 英文别名: N-tritylpropanamide
• CAS: 20808-84-8
• 化学式: C₂₂H₂₁NO
• 分子量: 315.415
• InChiKey: TYGIMLCCHCGIAY-UHFFFAOYSA-N

物化性质

• 熔点：
  193-194 °C
• 沸点：
  523.3±49.0 °C(Predicted)
• 密度：
  1.094±0.06 g/cm3(Temp: 20 °C; Press: 760 Torr)(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.7
• 重原子数：
  24
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  29.1
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  三苯基氯甲烷 、 丙酰胺 生成 N-Triphenylmethyl-propionamid
  参考文献：
  名称：

  Bredereck et al., Chemische Berichte, 1959, vol. 92, p. 1139,1146

  摘要：

  DOI：

文献信息

• GASTRIN RELEASING PEPTIDE COMPOUNDS
  申请人：Cappelletti Enrico

  公开号：US20110052491A1

  公开（公告）日：2011-03-03

  New and improved compounds for use in diagnostic imaging or therapy having the formula M—N—O—P—G, wherein M is an optical label or a metal chelator (in the form complexed with a metal radionuclide or not), N—O—P is the linker, and G is the GRP receptor targeting peptide. Methods for imaging a patient and/or providing radiotherapy or phototherapy to a patient using the compounds of the invention are also provided. Methods and kits for preparing a diagnostic imaging agent from the compound is further provided. Methods and kits for preparing a radiotherapeutic agent are further provided.

  本发明涉及用于诊断成像或治疗的新型化合物，其化学式为M—N—O—P—G，其中M是光学标记或金属螯合剂（以与金属放射性核素形成络合物或非络合形式存在），N—O—P是连接剂，G是GRP受体靶向肽。本发明还提供了使用该化合物进行患者成像和/或提供放射治疗或光疗的方法。本发明还提供了制备诊断成像剂的方法和试剂盒。本发明还提供了制备放射治疗剂的方法和试剂盒。
• Labeled gastrin releasing peptides (GRP)
  申请人：Bracco Imaging S.p.A

  公开号：EP2281580A2

  公开（公告）日：2011-02-09

  New and improved compounds for use in diagnostic imaging or therapy having the formula M-N-O-P-G, wherein M is an optical label or a metal chelator (in the form complexed with a metal radionuclide or not), N-O-P is the linker, and G is the GRP receptor targeting peptide. Methods for imaging a patient and/or providing radiotherapy or phototherapy to a patient using the compounds of the invention are also provided. Methods and kits for preparing a diagnostic imaging agent from the compound is further provided. Methods and kits for preparing a radiotherapeutic agent is further provided.

  用于诊断成像或治疗的新型改良化合物，其分子式为 M-N-O-P-G，其中 M 为光学标记或金属螯合剂（与金属放射性核素络合与否），N-O-P 为连接体，G 为 GRP 受体靶向肽。还提供了使用本发明化合物为患者成像和/或为患者提供放疗或光疗的方法。还提供了用本发明化合物制备诊断成像剂的方法和试剂盒。还提供了制备放射治疗剂的方法和试剂盒。
• Resist underlayer film-forming composition including a compound having an amino group protected with a tert-butoxycarbonyl group
  申请人：NISSAN CHEMICAL INDUSTRIES, LTD.

  公开号：US10242871B2

  公开（公告）日：2019-03-26

  There is provided a composition that a resist pattern having a reduced LWR representing variations in line width of the resist pattern, compared to conventional resist patterns, can be formed. A resist underlayer film-forming composition for lithography comprising a polymer, 0.1 to 30 parts by mass of a compound having an amino group protected with a tert-butoxycarbonyl group and an unprotected carboxyl group, or a hydrate of the compound, relative to 100 parts by mass of the polymer, and a solvent.

  本发明提供了一种组合物，与传统抗蚀剂图案相比，该组合物可形成具有较低 LWR 的抗蚀剂图案，代表抗蚀剂图案线宽的变化。一种用于光刻的抗蚀剂底层成膜组合物，包括聚合物、相对于 100 份聚合物质量的 0.1 至 30 份化合物（该化合物具有用叔丁氧羰基保护的氨基和未受保护的羧基）或该化合物的水合物，以及溶剂。
• Uses of Natriuretic Peptide Constructs
  申请人：PALATIN TECHNOLOGIES, INC.

  公开号：US20130274207A9

  公开（公告）日：2013-10-17

  Use of constructs which bind to one or more natriuretic peptide receptors and include a plurality of amino acid residues and at least one amino acid surrogate of formula I: where R, R′, Q, Y, W, Z, J, x and n are as defined in the specification, and optionally at least one prosthetic group, for the prophylaxis or treatment of airway diseases, including but not limited to inflammation-related airway diseases, acute asthma or COPD, methods of prophylaxis and treatment of airway diseases and pharmaceutical compositions and formulations for the prophylaxis or treatment of airway diseases.
• Replacement Therapy for Natriuretic Peptide Deficiencies
  申请人：Palatin Technologies, Inc.

  公开号：US20160354443A1

  公开（公告）日：2016-12-08

  Use and methods of use of natriuretic peptide mimetics which bind to and activate natriuretic peptide receptor A in patients with a defect, condition, syndrome, disease or mutation resulting in a functional active ANP 99-126 deficiency, for treatment or prophylaxis of cardiovascular disease, including but not limited to hypertension, acute coronary syndrome, cardiomyopathy, cardiac remodeling, left-ventricular hypertrophy, congestive heart failure, heart failure, high blood pressure and coronary artery disease, including use of mimetics with a plurality of amino acid residues and at least one amino acid surrogate of formula I: where R, R′, Q, Y, W, Z, J, x and n are as defined in the specification.